Health Populi November 14, 2024
Jane Sarasohn-Kahn

For health care, there are many uncertainties as we reflect, one week after the 2024 U.S. elections, on probably policy and market impacts that we can expect in 2025 and beyond. In today’s Health Populi post, I’ll reflect on the first of several certainties we-know-we-know about U.S. health citizens and key factors shaping the American health ecosystem.

In this first of several posts on “What Stays True for U.S. Health Care Post #Election2024,” I’ll focus on U.S. consumer dissatisfaction with drug prices — across political party identification.

Let’s set the context with data from a recently-published study from Navitus Health Solutions exploring 2,000 U.S. insured consumers’ perspectives on prescription drug pricing and the role of PBMs (pharmacy benefit managers)....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Patient / Consumer, Pharma, Pharma / Biotech
Trump picks RFK Jr. as HHS Secretary: 7 things to know
Trump names RFK Jr. as his pick to lead HHS
What's coming for the FTC? 5 things physicians need to know
How a Trump administration could shape the future of telehealth
How RFK Jr.'s MAHA movement could shake up public healt

Share This Article